PMID- 34566425
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220427
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 14
DP  - 2021
TI  - A Promising Esophageal Cancer Prognostic Signature of Ferroptosis-Related LncRNA 
      to Predict Immune Scenery and Immunotherapy Response.
PG  - 5845-5862
LID - 10.2147/IJGM.S327555 [doi]
AB  - PURPOSE: Ferroptosis and long non-coding RNA (lncRNA) expression signatures have 
      been associated with the clinical progression and immune-contexture of different 
      solid tumors. The study aimed to identify a prognostic signature of 
      ferroptosis-related lncRNAs (falncRNAs) to forecast the immune scenery and 
      immunotherapy response in esophageal cancer (EC). PATIENTS AND METHODS: Gene 
      expression profiles of EC were extracted from The Cancer Genome Atlas (TCGA) 
      database, and ferroptosis-related genes were downloaded from the FerrDb database, 
      which identified differentially expressed falncRNAs (DEfalncRNAs) via 
      differential analysis. DEfalncRNA pairs associated with prognosis were identified 
      by constructing a matrix, univariate and least absolute shrinkage and selection 
      operator (LASSO) analysis. The prognostic signature was constructed by 
      multivariate analysis. We appraised the forecasting capability of prognostic 
      signature in survival, clinicopathological features, immune landscape, efficacy 
      of immunotherapy, and drug sensitivity. The potential molecular mechanism of 
      signature was investigated by gene set enrichment analysis (GSEA). RESULTS: We 
      obtained 18 DEfalncRNA pairs to define a novel prognostic signature that was 
      determined on a discovery cohort of 158 tumor samples and 11 adjacent normal 
      tissues from TCGA and internally validated, with the definition of high- vs 
      low-risk groups based on 3 years overall survival. We demonstrated that the high- 
      vs low-risk groups differed for clinical parameters and computationally predicted 
      drug sensitivity and tumor immune contexture, with the high-risk group having 
      worse survival, more aggressive disease (node involvement, metastasis), reduced 
      drug sensitivity, higher tumor mutation load, and gene signatures of infiltration 
      of pro-tumoral immune cell subsets. The GSEA results revealed that ferroptosis 
      and immunoregulatory pathways were significantly enriched in the high-risk group. 
      CONCLUSION: The prognostic signature based on falncRNAs has the potential to 
      forecast the survival, immune scenery, efficacy of immunotherapy, and drug 
      sensitivity of EC, which is helpful for clinical prediction and individualized 
      treatment.
CI  - (c) 2021 Liu et al.
FAU - Liu, Xiaoxiao
AU  - Liu X
AUID- ORCID: 0000-0001-5582-9084
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Shi, Xiaobo
AU  - Shi X
AUID- ORCID: 0000-0002-0391-5076
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Guo, Wei
AU  - Guo W
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Ke, Yue
AU  - Ke Y
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Li, Yuxing
AU  - Li Y
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Pan, Shupei
AU  - Pan S
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Li, Xiaona
AU  - Li X
AD  - Department of Dermatology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Liu, Mei
AU  - Liu M
AD  - Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital 
      of Xi'an Jiaotong University, Xi'an, 710004, People's Republic of China.
FAU - Liu, Mingzhu
AU  - Liu M
AD  - Department of Gastroenterology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Wang, Yuchen
AU  - Wang Y
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Ruan, Qinli
AU  - Ruan Q
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
FAU - Ma, Hongbing
AU  - Ma H
AD  - Department of Radiation Oncology, Second Affiliated Hospital of Xi'an Jiaotong 
      University, Xi'an, 710004, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210918
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC8457888
OTO - NOTNLM
OT  - esophageal cancer
OT  - ferroptosis
OT  - immune
OT  - lncRNA
OT  - prognosis
OT  - signature
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/09/28 06:00
MHDA- 2021/09/28 06:01
PMCR- 2021/09/18
CRDT- 2021/09/27 05:58
PHST- 2021/07/02 00:00 [received]
PHST- 2021/08/23 00:00 [accepted]
PHST- 2021/09/27 05:58 [entrez]
PHST- 2021/09/28 06:00 [pubmed]
PHST- 2021/09/28 06:01 [medline]
PHST- 2021/09/18 00:00 [pmc-release]
AID - 327555 [pii]
AID - 10.2147/IJGM.S327555 [doi]
PST - epublish
SO  - Int J Gen Med. 2021 Sep 18;14:5845-5862. doi: 10.2147/IJGM.S327555. eCollection 
      2021.